Information Provided By: 
Fly News Breaks for May 31, 2019
ALKS
May 31, 2019 | 07:07 EDT
H.C. Wainwright analyst Douglas Tsao started Alkermes with a Neutral rating and $28 price target. While Vivitrol and Aristada should see continued growth, they're showing signs of maturity, necessitating Alkermes to bring new products to market to sustain growth, Tsao tells investors in a research note. The analyst also lacks conviction on the commercial potential of ALKS-3831.
News For ALKS From the Last 2 Days
